GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Y-Biologics Inc (XKRX:338840) » Definitions » Common Stock

Y-Biologics (XKRX:338840) Common Stock : ₩7,385 Mil (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Y-Biologics Common Stock?

Y-Biologics's quarterly common stock increased from Sep. 2023 (₩6,161 Mil) to Dec. 2023 (₩7,381 Mil) and increased from Dec. 2023 (₩7,381 Mil) to Mar. 2024 (₩7,385 Mil).

Y-Biologics's annual common stock increased from Dec. 2020 (₩5,763 Mil) to Dec. 2021 (₩6,141 Mil) and increased from Dec. 2021 (₩6,141 Mil) to Dec. 2022 (₩6,145 Mil).

Y-Biologics Common Stock Historical Data

The historical data trend for Y-Biologics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Y-Biologics Common Stock Chart

Y-Biologics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Common Stock
Get a 7-Day Free Trial 1,176.50 4,810.50 5,762.95 6,140.80 6,145.16

Y-Biologics Quarterly Data
Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Common Stock Get a 7-Day Free Trial Premium Member Only 6,160.95 6,160.95 6,160.95 7,381.36 7,384.76

Y-Biologics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Y-Biologics (XKRX:338840) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Y-Biologics Inc (XKRX:338840) » Definitions » Common Stock
Comparable Companies
Traded in Other Exchanges
N/A
Address
No. 715, 17, Tech-ro 4-ro, Yuseong-gu, Daejeon, KOR
Website
https://www.ybiologics.com
Y-Biologics Inc is a company has a variety of development candidate antibodies based on Korea's highest-level antibody discovery platform technology and then independently develops antibody treatments or jointly develops cutting-edge biopharmaceuticals by fusing them with our partner's platform technology. Its main business model is based on a globally competitive antibody discovery platform and consists of development of new bio drug candidates and early technology transfer, and contract research services that generate stable cash flow.

Y-Biologics (XKRX:338840) Headlines

No Headlines